Go Pro
OTCMKTS:PURE

PURE Bioscience (PURE) Stock Price, News & Analysis

PURE Bioscience logo
$0.06 +0.00 (+0.63%)
As of 08/3/2026 03:58 PM Eastern

About PURE Bioscience Stock (OTCMKTS:PURE)

Advanced

Key Stats

Today's Range
$0.06
$0.06
50-Day Range
$0.06
$0.09
52-Week Range
$0.04
$0.14
Volume
500 shs
Average Volume
21,633 shs
Market Capitalization
$8.37 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

PURE Bioscience, Inc. is a San Diego, California–based company that develops and markets patented antimicrobial solutions for diverse industries. At the core of its technology portfolio is Silver Dihydrogen Citrate (SDC), an EPA-registered broad-spectrum biocide designed to neutralize bacteria, viruses, and fungi on contact. The company targets applications in food processing, water treatment, personal care, and medical device sanitation.

PURE’s product suite includes concentrate formulations and ready-to-use solutions. Its food safety line offers surface sanitizers and processing aids approved by the U.S. Department of Agriculture (USDA) and the Food and Drug Administration (FDA) for direct contact with food-contact surfaces. The company also supplies biocidal chemistries for incorporation into personal care products such as shampoos and topical washes, as well as specialty solutions for water disinfection.

Founded in 2001, PURE Bioscience holds a portfolio of patents covering the generation and stabilization of SDC, which it licenses globally through distribution partnerships. The company serves customers across North America, with growing penetration into international markets via strategic alliances. PURE continues to expand its product approvals and registrations, reinforcing its position in regulated sectors that require validated antimicrobial efficacy.

PURE’s leadership team combines expertise in microbiology, regulatory affairs, and commercial operations to guide product development and market expansion. By focusing on scalable manufacturing processes, rigorous quality controls, and regulatory compliance, PURE Bioscience aims to address evolving public health needs with science-driven antimicrobial solutions.

AI Generated. May Contain Errors.

Receive PURE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PURE Bioscience and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

PURE Stock News Headlines

CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to trigger the next crash. The research firm Bernstein Research said this AI company has the power to crash the global economy for a decade, the CEO just issued a CODE RED in an internal memo warning employees they're dealing with a critical situation, and another company executive even implied they might need a government bailout. The last time I saw something like this was in 2008 when I predicted a stock market meltdown just three weeks before Lehman went under.tc pixel
See More Headlines

PURE Stock Analysis - Frequently Asked Questions

PURE Bioscience's stock was trading at $0.0420 on January 1st, 2026. Since then, PURE shares have increased by 53.3% and is now trading at $0.0644.

PURE Bioscience (OTCMKTS:PURE) announced its quarterly earnings data on Monday, June, 15th. The company reported ($0.01) earnings per share for the quarter. The company had revenue of $0.51 million for the quarter.

Shares of PURE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that PURE Bioscience investors own include Meta Platforms (META), Hydrofarm Holdings Group (HYFM), Twilio (TWLO), NVIDIA (NVDA), Enphase Energy (ENPH) and Novavax (NVAX).

Company Calendar

Last Earnings
6/15/2026
Today
8/04/2026
Fiscal Year End
7/31/2027

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Healthcare Equipment & Supplies
Sub-Industry
N/A
Current Symbol
OTCMKTS:PURE
CIK
1006028
Employees
10
Year Founded
1992

Profitability

EPS (Trailing Twelve Months)
($0.03)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$2.40 million
Net Margins
-109.59%
Pretax Margin
-65.45%
Return on Equity
N/A
Return on Assets
-321.74%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.42
Quick Ratio
0.36

Sales & Book Value

Annual Sales
$2.20 million
Price / Sales
3.81
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.05) per share
Price / Book
-1.29

Miscellaneous

Outstanding Shares
130,020,000
Free Float
83,784,000
Market Cap
$8.37 million
Optionable
Not Optionable
Beta
0.21

Social Links

Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

This page (OTCMKTS:PURE) was last updated on 8/4/2026 by MarketBeat.com Staff.
From Our Partners